ANDOVER, Mass., Jan. 05, 2026 (GLOBE NEWSWIRE) -- MKS Inc. (NASDAQ: MKSI), a global provider of enabling technologies that transform our world, today announced that John T.C. Lee, President and Chief Executive Officer, will participate in a fireside chat at Needham’s 28th Annual Growth Conference on Tuesday, January 13, 2026 at 11:00 a.m. EST. A live webcast of the session will be available in the Investor Relations section of the company's website at https://investor.mksinst.com/events-and-presentations an ...

About Agilent Technologies Agilent Technologies, Inc. (NYSE: A) is a global leader in analytical and clinical laboratory technologies, delivering insights and innovation that help our customers bring great science to life. Agilent's full range of solutions includes instruments, software, services, and expertise that provide trusted answers to our customers' most challenging questions. The company generated revenue of $6.95 billion in fiscal year 2025 and employs approximately 18,000 people worldwide. Inform ...

For new and old investors, taking full advantage of the stock market and investing with confidence are common goals. Zacks Premium provides lots of different ways to do both.Featuring daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, the research service can help you become a smarter, more self-assured investor.Zacks Premium also includes the Zacks Style Scores. What are the Zacks Style Scores? The Zacks Style ...

Company Overview - Agilent Technologies, Inc. has a market cap of $42.3 billion and provides application-focused solutions for life sciences, diagnostics, and applied chemical markets globally [1] - The company operates through three segments: Life Sciences and Applied Markets; Diagnostics and Genomics; and Agilent CrossLab, offering a wide range of instruments, consumables, software, and laboratory services [1] Stock Performance - Agilent's shares have decreased by 6.9% from its 52-week high of $160.27, but have increased by 19.2% over the past three months, outperforming The Health Care Select Sector SPDR Fund's (XLV) 13.3% gain during the same period [3] - Over the past 52 weeks, Agilent's stock has risen by 7.2%, surpassing XLV's 5.6% return, but is up only 11.1% year-to-date, lagging behind XLV's 12.7% return [4] Financial Results - Following its Q4 2025 results, Agilent's shares rose by 2.3%, with revenue of $1.86 billion exceeding estimates and adjusted EPS of $1.59 meeting expectations [5] - Key segments showed strong performance, with Life Sciences and Diagnostics revenue at $755 million and a 7% increase in CrossLab revenue to $775 million [5] - The company projects fiscal 2026 revenue between $7.3 billion and $7.4 billion, with adjusted EPS expected to be between $5.86 and $6 [5] Competitive Landscape - Despite Agilent's positive outlook, rival Eli Lilly and Company has outperformed, with LLY stock surging 33.9% year-to-date and 27.1% over the past 52 weeks [6] - Analysts maintain a moderately optimistic view on Agilent, with a consensus rating of "Moderate Buy" from 17 analysts and a mean price target of $169.62, indicating a 13.6% premium to current levels [6]

导读： 2025年 第12期高校仪器采购意向汇总来了。全国各大高校发布仪器采购意向，预算总额 达68亿以上 。 特别提示 微信公众号机制调整，请点击顶部"仪器信息网" → 右上方"…" → 设为 ★ 星标，否则很可能无法看到我们的推送。 2025年11月，高校科研院所的仪器设备采购热度不减，小编汇总了11月发布的55 所高校及科研院所部分大宗仪器采 购意向，预算总额 达68亿 以上： 2025年11月高校科研院所仪器设备采购意向汇总清单 （ 点 击 学 校 名 称 查 看 详 细 采 购 需求） | 采购院校 | 金额 | | --- | --- | | | 亿元 | | 北京大学 | 1.34 | | 复旦大学 | 1.03 | | 安徽大学 | 0.99 | | 北京理工大学 | 1.27 | | 海南大学 | 1.08 | | 上海科技大学 | 1.54 | | 四川农业大学 | 1.18 | | 浙江大学 | 1.06 | | 中国科学院大连化物所 | 1.00 | | 中国科学院近代物理研究所 | 1.05 | | 中国科学技术大学 | 1.41 | | | 1.29 | 中国中医科学院 | 空天信 ...

Danaher Corporation (NYSE:DHR) is one of the stocks Jim Cramer recently discussed. Cramer noted that he still likes the stock for the Charitable Trust, as he said: “Now, first, there’s tried and true, but lately trying Danaher, DHR, a conglomerate that became more focused on life sciences diagnostics when it spun off its water and product quality testing business as Veralto a couple years ago. We own Danaher for the Charitable Trust. I gotta tell you, it’s been really frustrating for the past couple years ...

Agilent Technologies, Inc. (NYSE:A) is one of the stocks Jim Cramer recently discussed. Cramer discussed the company’s performance over the longer term, as he commented: “Last week, just before Thanksgiving, I got the chance to speak with Agilent Technologies. That’s an arms dealer to the life sciences industry. A long time ago, this stock, known as letter A for its stock symbol, was a great growth vehicle. In the decade before COVID, Agilent’s chart was just a thing of beauty. Then, when the pandemic got ...

Core Insights - MKS Inc. has been recognized as one of America's Most Responsible Companies for 2026 by Newsweek and Statista, marking the third consecutive year of this recognition [1][2]. Company Overview - MKS Inc. (NASDAQ: MKSI) provides enabling technologies that transform various industries, focusing on semiconductor manufacturing, electronics, packaging, and specialty industrial applications [5]. - The company delivers foundational technology solutions that enhance process performance, optimize productivity, and enable innovations for leading technology and industrial companies [5]. - MKS's solutions address challenges related to miniaturization and complexity in advanced device manufacturing, as well as increasing performance requirements across various industrial applications [5]. Recognition Criteria - The ranking of America's Most Responsible Companies evaluates the top 2,000 public U.S.-based companies by revenue, using over 30 key performance indicators and a public survey of 18,000 U.S. residents [4].

Core Insights - MKS Inc. will participate in a fireside chat at the Nasdaq 53 Investor Conference on December 9, 2025, at 6:00 a.m. EST [1] - A live webcast of the session will be available on the company's Investor Relations website, with a replay accessible for a limited time afterward [2] Company Overview - MKS Inc. is a global provider of enabling technologies that transform various industries, focusing on semiconductor manufacturing, electronics, packaging, and specialty industrial applications [3] - The company delivers foundational technology solutions, including instruments, subsystems, systems, process control solutions, and specialty chemicals technology, aimed at improving process performance and optimizing productivity [3] - MKS's solutions address challenges related to miniaturization and complexity in advanced device manufacturing, enhancing power, speed, features, and connectivity [3]

Core Insights - Danaher Corporation (DHR) is a global leader in science and technology, focusing on innovation in life sciences, diagnostics, and biotechnology, with a market cap of $152.4 billion [1] Performance Overview - DHR has underperformed the broader market over the past 52 weeks, with shares declining 8.4%, while the S&P 500 Index gained 14.5% [2] - Year-to-date, DHR's stock is down 4.4%, compared to a 16.5% return for the S&P 500 [2] - DHR has also lagged behind the iShares U.S. Healthcare ETF, which saw a 3.4% increase over the past 52 weeks and a 10.3% rise year-to-date [3] Recent Financial Results - DHR's shares rose 5.9% following impressive Q3 results, with revenue increasing 4.4% year-over-year to $6.1 billion, surpassing consensus estimates [4] - The adjusted EPS for Q3 was $1.89, improving 10.5% from the previous year and exceeding analyst expectations of $1.71 [4] - Key contributors to the positive performance included DBS-driven execution, momentum in the bioprocessing business, and better-than-expected respiratory revenue at Cepheid [4] Future Earnings Expectations - For the current fiscal year ending in December, analysts expect DHR's EPS to grow 3.2% year-over-year to $7.72 [5] - DHR has a mixed earnings surprise history, topping consensus estimates in three of the last four quarters [5] Analyst Ratings - Among 22 analysts covering DHR, the consensus rating is a "Strong Buy," with 18 "Strong Buy" and four "Hold" ratings [5] - Recently, Wells Fargo maintained an "Equal Weight" rating on DHR and raised its price target to $230, indicating a potential upside of 4.8% from current levels [6]